324 related articles for article (PubMed ID: 33766422)
1. Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled trial.
Beissbarth J; Wilson N; Arrowsmith B; Binks MJ; Oguoma VM; Lawrence K; Llewellyn A; Mulholland EK; Santosham M; Morris PS; Smith-Vaughan HC; Cheng AC; Leach AJ
Vaccine; 2021 Apr; 39(16):2264-2273. PubMed ID: 33766422
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
[TBL] [Abstract][Full Text] [Related]
3. 10-Valent pneumococcal non-typeable
Oguoma VM; Wilson N; Mulholland K; Santosham M; Torzillo P; McIntyre P; Smith-Vaughan H; Balloch A; Chatfield M; Lehmann D; Binks MJ; Chang A; Carapetis J; Krause V; Andrews R; Snelling T; Licciardi P; Morris P; Leach AJ
BMJ Open; 2020 May; 10(5):e033511. PubMed ID: 32448790
[TBL] [Abstract][Full Text] [Related]
4. Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.
Leach AJ; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Wilson N; Arrowsmith B; Beissbarth J; Chatfield MD; Oguoma VM; Morris PS
BMC Pediatr; 2021 Mar; 21(1):117. PubMed ID: 33685411
[TBL] [Abstract][Full Text] [Related]
5. General health, otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate vaccines.
Leach AJ; Wigger C; Beissbarth J; Woltring D; Andrews R; Chatfield MD; Smith-Vaughan H; Morris PS
Int J Pediatr Otorhinolaryngol; 2016 Jul; 86():224-32. PubMed ID: 27260611
[TBL] [Abstract][Full Text] [Related]
6. Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine.
Leach AJ; Wigger C; Hare K; Hampton V; Beissbarth J; Andrews R; Chatfield M; Smith-Vaughan H; Morris PS
BMC Pediatr; 2015 Oct; 15():162. PubMed ID: 26482232
[TBL] [Abstract][Full Text] [Related]
7. Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal
Leach AJ; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Wilson N; Arrowsmith B; Beissbarth J; Chatfield MD; Oguoma VM; Licciardi P; Skull S; Andrews R; Carapetis J; McDonnell J; Krause V; Morris PS
Vaccine X; 2021 Apr; 7():100086. PubMed ID: 33681756
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland.
Vesikari T; Forsten A; Seppä I; Kaijalainen T; Puumalainen T; Soininen A; Traskine M; Lommel P; Schoonbroodt S; Hezareh M; Moreira M; Borys D; Schuerman L
J Pediatric Infect Dis Soc; 2016 Sep; 5(3):237-248. PubMed ID: 27125273
[TBL] [Abstract][Full Text] [Related]
9. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil.
Brandileone MC; Zanella RC; Almeida SCG; Brandao AP; Ribeiro AF; Carvalhanas TMP; Sato H; Andrade AL; Verani JR;
Vaccine; 2016 Nov; 34(46):5604-5611. PubMed ID: 27692770
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of Otitis Media with Spontaneous Perforation of the Tympanic Membrane in Young Children and Association with Bacterial Nasopharyngeal Carriage, Recurrences and Pneumococcal Vaccination in Catalonia, Spain - The Prospective HERMES Study.
Cilveti R; Olmo M; Pérez-Jove J; Picazo JJ; Arimany JL; Mora E; Pérez-Porcuna TM; Aguilar I; Alonso A; Molina F; Del Amo M; Mendez C;
PLoS One; 2017; 12(2):e0170316. PubMed ID: 28146590
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial.
Sáez-Llorens X; Rowley S; Wong D; Rodríguez M; Calvo A; Troitiño M; Salas A; Vega V; Castrejón MM; Lommel P; Pascal TG; Hausdorff WP; Borys D; Ruiz-Guiñazú J; Ortega-Barría E; Yarzabal JP; Schuerman L
Hum Vaccin Immunother; 2017 Jun; 13(6):1-16. PubMed ID: 28368738
[TBL] [Abstract][Full Text] [Related]
13. Otitis media at 6-monthly assessments of Australian First Nations children between ages 12-36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines.
Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Skull SA; Oguoma VM; Chatfield M; Lehmann D; Binks MJ; Licciardi PV; Andrews R; Snelling T; Krause V; Carapetis J; Chang AB; Morris PS
Int J Pediatr Otorhinolaryngol; 2023 Dec; 175():111776. PubMed ID: 37951020
[TBL] [Abstract][Full Text] [Related]
14. The short-term impact of each primary dose of pneumococcal conjugate vaccine on nasopharyngeal carriage: Systematic review and meta-analyses of randomised controlled trials.
Nicholls TR; Leach AJ; Morris PS
Vaccine; 2016 Feb; 34(6):703-13. PubMed ID: 26742947
[TBL] [Abstract][Full Text] [Related]
15. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
de Sévaux JL; Venekamp RP; Lutje V; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD001480. PubMed ID: 33231293
[TBL] [Abstract][Full Text] [Related]
16. Impact of HIV status and vaccination schedule on bacterial nasopharyngeal carriage following infant immunisation with the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in South Africa.
Madhi SA; Moreira M; Koen A; van Niekerk N; de Gouveia L; Jose L; Cutland CL; François N; Schoonbroodt S; Ruiz-Guiñazú J; Yarzabal JP; Borys D; Schuerman L
Vaccine; 2020 Feb; 38(10):2350-2360. PubMed ID: 32035706
[TBL] [Abstract][Full Text] [Related]
17. Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial.
Leach AJ; Mulholland EK; Santosham M; Torzillo PJ; Brown NJ; McIntyre P; Smith-Vaughan H; Skull S; Balloch A; Andrews R; Carapetis J; McDonnell J; Krause V; Morris PS
BMJ Open; 2015 Jan; 5(1):e007247. PubMed ID: 25596202
[TBL] [Abstract][Full Text] [Related]
18. Pneumococcal vaccine impact on otitis media microbiology: A New Zealand cohort study before and after the introduction of PHiD-CV10 vaccine.
Best EJ; Walls T; Souter M; Neeff M; Anderson T; Salkeld L; Ahmad Z; Mahadevan M; Walker C; Murdoch D; Mills N
Vaccine; 2016 Jul; 34(33):3840-7. PubMed ID: 27265454
[TBL] [Abstract][Full Text] [Related]
19. Can two different pneumococcal conjugate vaccines be used to complete the infant vaccination series? A randomized trial exploring interchangeability of the 13-valent pneumococcal conjugate vaccine and the pneumococcal non-typeable
de Los Santos AM; Rodríguez-Weber MA; Sánchez-Márquez P; Traskine M; Carreño-Manjarrez R; Cervantes-Apolinar MY; Strezova A; Ruiz-Guiñazú J; Ortega-Barria E; Borys D
Expert Rev Vaccines; 2020 Nov; 19(11):995-1010. PubMed ID: 33297773
[No Abstract] [Full Text] [Related]
20. Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease.
Izurieta P; Nieto Guevara J
Hum Vaccin Immunother; 2022 Dec; 18(1):1872341. PubMed ID: 33605846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
